These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 11455982)

  • 21. [Impact of immunochemotherapy on survival of patients with metastatic renal cell carcinoma. A retrospective study comparing interferon-alpha-2a/vinblastine versus interferon-alpha-2a/interleukin-2/5-fluorouracil].
    May M; Helke C; Bock M; Hoschke B
    Urologe A; 2004 Sep; 43(9):1111-9. PubMed ID: 15232686
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CHOP-Bleo plus interferon for stage IV low-grade lymphoma.
    McLaughlin P; Cabanillas F; Hagemeister FB; Swan F; Romaguera JE; Taylor S; Rodriguez MA; Velasquez WS; Redman JR; Gutterman JU
    Ann Oncol; 1993 Mar; 4(3):205-11. PubMed ID: 7682436
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prednimustine, mitoxantrone (PmM) vs cyclophosphamide, vincristine, prednisone (COP) for the treatment of advanced low-grade non-Hodgkin's lymphoma. German Low-Grade Lymphoma Study Group.
    Unterhalt M; Herrmann R; Tiemann M; Parwaresch R; Stein H; Trümper L; Nahler M; Reuss-Borst M; Tirier C; Neubauer A; Freund M; Kreuser ED; Dietzfelbinger H; Bodenstein H; Engert A; Stauder R; Eimermacher H; Landys K; Hiddemann W
    Leukemia; 1996 May; 10(5):836-43. PubMed ID: 8656680
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase II study of fludarabine combined with interferon-alpha-2a followed by maintenance therapy with interferon-alpha-2a in patients with low-grade non-hodgkin's lymphoma.
    Lynch JW; Hei DL; Braylan RC; Rimzsa LM; Staab EV; Bewsher CJ; Mendenhall NP; Hudson JK
    Am J Clin Oncol; 2002 Aug; 25(4):391-7. PubMed ID: 12151972
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Advanced diffuse non-Hodgkin's lymphoma. Analysis of prognostic factors by the international index and by lactic dehydrogenase in an intergroup study.
    Gordon LI; Andersen J; Colgan J; Glick J; Resnick GD; O'Connell M; Cassileth PA
    Cancer; 1995 Feb; 75(3):865-73. PubMed ID: 7530168
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rituximab-CHOP-ESHAP vs CHOP-ESHAP-high-dose therapy vs conventional CHOP chemotherapy in high-intermediate and high-risk aggressive non-Hodgkin's lymphoma.
    Intragumtornchai T; Bunworasate U; Nakorn TN; Rojnuckarin P
    Leuk Lymphoma; 2006 Jul; 47(7):1306-14. PubMed ID: 16923561
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase I/II study of cyclophosphamide, carboplatin, and etoposide and autologous hematopoietic stem-cell transplantation with posttransplant interferon alfa-2b for patients with lymphoma and Hodgkin's disease.
    Schenkein DP; Dixon P; Desforges JF; Berkman E; Erban JK; Ascensao JL; Miller KB
    J Clin Oncol; 1994 Nov; 12(11):2423-31. PubMed ID: 7964959
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The cyclophosphamide, vincristine, prednisone, bleomycin, doxorubicin, and procarbazine (COPBLAM-I) regimen for intermediate-grade non-Hodgkin's lymphoma. Long term follow-up in 51 patients.
    Shpilberg O; Shiff J; Chetrit A; Ramot B; Ben-Bassat I
    Cancer; 1994 Dec; 74(11):3029-33. PubMed ID: 7525042
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CEOP-B alternated with VIMB in intermediate-grade and high-grade non-Hodgkin's lymphoma: a pilot study.
    De Lena M; Ditonno P; Lorusso V; Brandi M; Timurian A; Marzullo F; Ventrella V; Pellecchia A
    J Clin Oncol; 1995 Apr; 13(4):953-60. PubMed ID: 7535844
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term results of a multicentre randomised, comparative phase III trial of CHOP versus CNOP regimens in patients with intermediate- and high-grade non-Hodgkin's lymphomas. Novantrone International Study Group.
    Bezwoda W; Rastogi RB; Erazo Valla A; Diaz-Maqueo JC; Pavlovsky S; Morioka H; Resegotti L; Rueckle H; Somoza N; Moreno-Nogueira JA
    Eur J Cancer; 1995 Jun; 31A(6):903-11. PubMed ID: 7646919
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma.
    Fisher RI; Gaynor ER; Dahlberg S; Oken MM; Grogan TM; Mize EM; Glick JH; Coltman CA; Miller TP
    N Engl J Med; 1993 Apr; 328(14):1002-6. PubMed ID: 7680764
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Risk factors for treatment-related death in elderly patients with aggressive non-Hodgkin's lymphoma: results of a multivariate analysis.
    Gómez H; Hidalgo M; Casanova L; Colomer R; Pen DL; Otero J; Rodríguez W; Carracedo C; Cortés-Funes H; Vallejos C
    J Clin Oncol; 1998 Jun; 16(6):2065-9. PubMed ID: 9626205
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adjuvant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy after radiation therapy in stage I low-grade and intermediate-grade non-Hodgkin lymphoma. Results of a prospective randomized study.
    Yahalom J; Varsos G; Fuks Z; Myers J; Clarkson BD; Straus DJ
    Cancer; 1993 Apr; 71(7):2342-50. PubMed ID: 8453557
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A cooperative study of epirubicin with cyclophosphamide, vincristine and prednisone (CEOP) in non-Hodgkin's lymphoma.
    Lambertenghi Deliliers G; Butti C; Baldini L; Ceriani A; Lombardi F; Luoni M; Montalbetti L; Pavia G; Pinotti G; Pogliani E
    Haematologica; 1995; 80(4):318-24. PubMed ID: 7590500
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Treatment effect of DICE regimen on patients with relapsed or refractory intermediate and high grade non-Hodgkin's lymphoma].
    Zhou SY; Shi YK; He XH; Zhang P; Dong M; Huang DZ; Yang JL; Zhang CG; Liu P; Yang S; Feng FY
    Ai Zheng; 2005 Apr; 24(4):465-9. PubMed ID: 15820071
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of intermediate- and high-grade non-Hodgkin's lymphoma using CEOP versus CNOP.
    Economopoulos T; Dimopoulos MA; Mellou S; Pavlidis N; Samantas E; Nicolaides C; Tsatalas C; Papadopoulos A; Papageogriou E; Papasavvas P; Fountzilas G
    Eur J Haematol; 2002 Mar; 68(3):135-43. PubMed ID: 12068793
    [TBL] [Abstract][Full Text] [Related]  

  • 37. VAPEC-B chemotherapy in the treatment of aggressive non-Hodgkin's lymphoma: a retrospective analysis of 45 patients.
    Singer JM; Mijovic A; Pettingale KW; Nethersell A; Dobbs HJ; Samaratunga IR; Lakhani A; Mufti GJ
    Clin Oncol (R Coll Radiol); 1995; 7(6):366-70. PubMed ID: 8590697
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term follow-up of a prospective study of combined modality therapy for stage I-II indolent non-Hodgkin's lymphoma.
    Seymour JF; Pro B; Fuller LM; Manning JT; Hagemeister FB; Romaguera J; Rodriguez MA; Ha CS; Smith TL; Ayala A; Hess M; Cox JD; Cabanillas F; McLaughlin P
    J Clin Oncol; 2003 Jun; 21(11):2115-22. PubMed ID: 12775737
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interferon alpha 2b as maintenance therapy in low grade malignant lymphoma improves duration of remission and survival.
    Aviles A; Duque G; Talavera A; Guzman R
    Leuk Lymphoma; 1996 Feb; 20(5-6):495-9. PubMed ID: 8833409
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A pilot study on the use of the ProMACE-CytaBOM regimen as a first-line treatment of advanced follicular non-Hodgkin's lymphoma. Gruppo Italiano per lo Studio dei Linfomi.
    Baldini L; Guffanti A; Gobbi P; Colombi M; Federico M; Avanzini P; Cavanna L; Pieresca C; Silingardi V; Maiolo AT
    Cancer; 1997 Mar; 79(6):1234-40. PubMed ID: 9070503
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.